We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.
We presented two posters at AACR describing how high-throughput transcriptomics is helping to identify novel GPX4 inhibitors.
In collaboration with Forma Therapeutics, Arpeggio uses their transcriptional platform to uncover novel mechanisms of CBP inhibitors.
Arpeggio featured in a great write up by Paul Schloesser on how we're building our drug pipeline and discovery platform.
A feature on Arpeggio and our mission to bring new medicine to patients with cancer and rare disease.
Arpeggio will be a presenting company as well as forming connections through BIO one-on-one partnering throughout the week.
We were selected to pitch at Destination Startup Ventures 2021, a showcase featuring the best companies from across the Rocky Mountain Region.
Arpeggio was featured in the Colorado BioScience Association’s annual publication: “Arpeggio Biosciences: Fusing Big Data With Molecular Biology”
Joey was a featured speaker, presenting: "Drugging Oncogenic Transcription Factors with Enhancer Activity Screen"
Arpeggio announces: "Arpeggio Bio raises $3.2 million in seed funding and CEO named to the 2020 Forbes 30 Under 30 list in healthcare"
Forma Therapeutics announces partnership with Arpeggio: “Celgene-partnered Forma teams with Arpeggio to understand drug-target interactions”
Have questions? Interested in partnering with Arpeggio? Let us know.
